Sun Pharmaceutical Industries Ltd. announced on Monday that it has entered into a global licensing agreement with Swiss-Italian biotech firm Philogen to commercialize the specialty anti-cancer immunotherapy, Fibromun (L19TNF). This innovative treatment is currently under investigation in registration trials for the treatment of soft tissue